Appia Bio
JJ Kang, Ph.D., is co-founder and CEO. She is a venture partner at The Column Group since 2020 and serves on the boards of directors of Tenaya Therapeutics and Escient Pharmaceuticals. JJ held roles of increasing responsibility on the investment team at The Column Group since joining in 2015 and last served as a partner prior to joining Appia Bio. Previously, she worked at FibroGen in project management and corporate strategy. JJ earned a PhD in chemical biology at Caltech and a BA in chemistry from Harvard University.
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).